Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

618 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, Advani RH, Fenske TS, Barta SK, Palmisiano ND, Svoboda J, Morgan DS, Karmali R, Sharon E, Streicher H, Kahl BS, Ansell SM. Diefenbach CS, et al. Among authors: svoboda j. Lancet Haematol. 2020 Sep;7(9):e660-e670. doi: 10.1016/S2352-3026(20)30221-0. Lancet Haematol. 2020. PMID: 32853585 Free PMC article. Clinical Trial.
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy.
Carreau NA, Armand P, Merryman RW, Advani RH, Spinner MA, Herrera AF, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Nathan S, Karmali R, Torka P, David K, Lansigan F, Persky D, Godfrey J, Chavez JC, Xia Y, Diefenbach C. Carreau NA, et al. Among authors: svoboda j. Br J Haematol. 2020 Oct;191(1):44-51. doi: 10.1111/bjh.16756. Epub 2020 May 19. Br J Haematol. 2020. PMID: 32430944 Free article.
R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J. Shah NN, et al. Among authors: svoboda j. Br J Haematol. 2018 Feb;180(4):534-544. doi: 10.1111/bjh.15051. Epub 2017 Dec 19. Br J Haematol. 2018. PMID: 29265182 Free article.
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma.
Merryman RW, Carreau NA, Advani RH, Spinner MA, Herrera AF, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David KA, Wei C, Lansigan F, Emery L, Persky D, Smith SM, Godfrey J, Chavez J, Cohen JB, Troxel AB, Diefenbach C, Armand P. Merryman RW, et al. Among authors: svoboda j. Oncologist. 2020 Jun;25(6):e993-e997. doi: 10.1634/theoncologist.2020-0040. Epub 2020 Apr 28. Oncologist. 2020. PMID: 32275786 Free PMC article.
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
Svoboda J, Bair SM, Landsburg DJ, Dwivedy Nasta S, Nagle SJ, Barta SK, Khan N, Filicko-O'Hara J, Gaballa S, Strelec L, Chong E, Mitnick S, Waite TS, King C, Ballard H, Youngman M, Gerson J, Plastaras JP, Maity A, Bogusz AM, Hung SS, Nakamura H, Nejati R, Steidl C, Lim M, Ruella M, Schuster SJ. Svoboda J, et al. Haematologica. 2021 Jun 1;106(6):1705-1713. doi: 10.3324/haematol.2019.238675. Haematologica. 2021. PMID: 32414850 Free PMC article. Clinical Trial.
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy.
Carreau NA, Pail O, Armand P, Merryman R, Advani RH, Spinner MA, Herrera A, Chen R, Tomassetti S, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta S, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, Godfrey J, Chavez J, Xia Y, Troxel AB, Diefenbach C. Carreau NA, et al. Among authors: svoboda j. Oncologist. 2020 Oct;25(10):878-885. doi: 10.1634/theoncologist.2020-0167. Epub 2020 Aug 28. Oncologist. 2020. PMID: 32720734 Free PMC article.
Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome.
Lewis DJ, Haun PL, Samimi SS, Vittorio CC, Villasenor-Park J, Barta SK, Landsburg DJ, Svoboda J, Nasta SD, Schuster SJ, Rook AH, Kim EJ. Lewis DJ, et al. Among authors: svoboda j. JAMA Dermatol. 2021 Mar 1;157(3):317-321. doi: 10.1001/jamadermatol.2020.4901. JAMA Dermatol. 2021. PMID: 33377934 Free PMC article.
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, Rao U, Byrne MT, Bond DA, Maddocks KJ, Spinner MA, Advani RH, Ballard HJ, Svoboda J, Singh AK, McGuirk JP, Modi D, Ramchandren R, Romancik J, Cohen JB, Frigault MJ, Chen YB, Serritella AV, Kline J, Ansell S, Nathan S, Rahimian M, Joyce RM, Shah M, David KA, Park S, Beaven AW, Habib A, Bachanova V, Nakhoda S, Khan N, Lynch RC, Smith SD, Ho VT, LaCasce A, Armand P, Herrera AF. Merryman RW, et al. Among authors: svoboda j. Blood Adv. 2021 Mar 23;5(6):1648-1659. doi: 10.1182/bloodadvances.2020003556. Blood Adv. 2021. PMID: 33710337 Free PMC article.
Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma.
Orellana-Noia VM, Isaac K, Malecek MK, Bartlett NL, Voorhees TJ, Grover NS, Hwang SR, Bennani NN, Hu R, Hill BT, Mou E, Advani RH, Carter J, David KA, Ballard HJ, Svoboda J, Churnetski MC, Magarelli G, Feldman TA, Cohen JB, Evens AM, Portell CA. Orellana-Noia VM, et al. Among authors: svoboda j. Blood Adv. 2021 Sep 28;5(18):3623-3632. doi: 10.1182/bloodadvances.2021004645. Blood Adv. 2021. PMID: 34448831 Free PMC article.
618 results